Certolizumab Pegol for the Treatment of Moderate to Severe Plaque Psoriasis: 16-Week Results from a Phase 2/3 Japanese Study

INTRODUCTION: Certolizumab pegol (CZP), the Fc-free, PEGylated anti-tumor necrosis factor, is approved for the treatment of moderate to severe plaque psoriasis (PSO) in Western countries and in Japan, among other indications. METHODS: We report results from the first 16 weeks of a 52-week phase 2/3...

Descripción completa

Detalles Bibliográficos
Autores principales: Umezawa, Yoshinori, Sakurai, Shinya, Hoshii, Naoki, Nakagawa, Hidemi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019007/
https://www.ncbi.nlm.nih.gov/pubmed/33606269
http://dx.doi.org/10.1007/s13555-021-00494-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019007/
https://www.ncbi.nlm.nih.gov/pubmed/33606269
http://dx.doi.org/10.1007/s13555-021-00494-z

Ejemplares similares